# Limulus Venture Partners

Limulus Venture Partners is a Venture Capital based in Boston, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** Boston, MA, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** limulusventures.com
- **LinkedIn:** https://www.linkedin.com/company/limulus-venture-capital

## Regulatory record

- **CRD number:** 301886
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/301886

## About

Limulus Venture Partners | A venture capital firm focusing on investments in the biotechnology sector.

## Sectors

- Biotechnology

## Questions

### What is Limulus Venture Partners' investment focus?

Limulus Venture Partners invests exclusively in the biotechnology sector, targeting early-stage companies. The firm focuses on novel therapeutics and platform technologies, operating at the seed and Series A stages from its base in Boston.

### How does Limulus Venture Partners source deals given its narrow biotechnology focus?

The firm leverages its location in the Boston biotechnology cluster, one of the most concentrated hubs for academic spinouts and early-stage drug-discovery companies globally. Proximity to top-tier research institutions and talent pools is a structural advantage for proprietary sourcing.

### Does Limulus Venture Partners lead rounds or primarily co-invest?

The firm's stated deployment strategy centers on direct equity investments at the earliest stages. Public disclosure of specific deal structures, lead versus follow-on participation, and check sizes is not currently available.

### Is Limulus Venture Partners sector-agnostic within life sciences, or does it have sub-sector preferences?

Based on available information, the firm's biotechnology focus includes both novel therapeutics and enabling platform technologies. A finer breakdown of sub-sector preferences, such as small molecule versus biologics or specific therapeutic areas, has not been publicly detailed.

### What is the firm's track record or number of exits in biotechnology?

Detailed portfolio holdings, exits, and deployment metrics have not been publicly disclosed by the firm. Without a public portfolio list, track record cannot be independently assessed.

## Related profiles

- [Limestone Value Partners](https://altss.com/profile/limestone-value-partners-llc)
- [Linden Ash Capital](https://altss.com/profile/linden-ash-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/limulus-venture-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology